Nektar Launches Phase 2 Study for Chronic Pain Drug
Nektar Therapeutics has launched a Phase 2 study of the opioid analgesic NKTR-181, according to a company release.
NKTR-181 is designed to have a slow rate of entry into the brain and reduce side effects such as sedation and respiratory depression. The double-blind, placebo-controlled clinical study will assess the safety and tolerability of the drug in patients with moderate to severe chronic pain from osteoarthritis of the knee.
The study will enroll approximately 200 patients.
Related Articles on Pain Management:Relmada Raises $3M to Develop LevoCap Painkiller
Pain Specialist Dr. David Cheng Joins Midwest Orthopaedics
Middle Fork Surgery Center Visited by Oregon's Co-Speaker of the House
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- How Physician Thinking Changes After Working in ACOs
- 2014 Financial Impact Analysis Doesn't Stop With CMS' Final Rule: Don't Neglect CMS NCCI Edits
- 4 Drivers of Recent M&A Activity in Healthcare
- 8 Reasons to Outsource Medical Billing Services
- 5 ICD-10 Transition Considerations Medical Practices Have Likely Not Thought About